For Research Use Only. Not for Use in Diagnostic Procedures.
This webinar will describe the integration of biology and engineering to devise simple, high-throughput 3D human microtissues as predictive biology platforms that reflect human physiology and disease, solving fundamental questions of adverse biological response with the goal of modernizing toxicity and drug candidate testing.
A key aspect of this approach is the implementation of “in vitro pathology”, making use of quantitative metrics from reconstructed 3D microtissue images to discern adverse biological effects. This strategy is currently being used to develop 3D microtissues of a variety of human tissues, exploring the utility of single cell lines, co-cultures of cells, and human induced pluripotent stem cells. The goal is to access a wide variety of cellular behavior, characterizing responses across the biological landscape using simple and rapid techniques.
In this webinar the presenters discuss the value that high-content imaging and analysis can bring to your cell biology research program.
They describe how you can exploit the full potential of automated microscopy to gain more meaningful information to address biological questions from your cellular samples whilst improving your lab’s throughput, productivity, and overall efficacy. They show solutions to the challenges of interrogating more physiologically relevant and complex cell model systems, such as co-cultures, 3D cell models, and tissues.
In this webinar the speakers describe the marriage of 3D organoids and high-content screening (HCS) to discover targeted drug therapies effective against the malignant phenotype in colorectal cancer (CRC). The CRC tumor organoid model described features an innovative dual reporter of epithelial-mesenchymal transition (EMT), including: E-cadherin promoter red fluorescent protein and vimentin promoter green fluorescent protein cloned into a single pCDH1 lentiviral vector.
The speakers also describe a robust methodology for automated tumor organoid culture and validated 3D high-content analysis algorithms. Using these approaches they have screened a focused library of 3,000 small molecule compounds and have identified and validated hits that promote the reversion of EMT in CRC.
In this webinar, learn how PPIs can be studied at higher throughput using a FRET-based assay on the Opera Phenix™ high-content screening system. By taking advantage of simultaneous confocal imaging with the system’s four cameras, a fast and robust FRET-based assay to measure the interaction of the anti-apoptotic protein Bcl-XL with the pro-apoptotic protein Bad was established
The speakers also explain the benefits of the proprietary Synchrony™ optics technology for FRET-based assays and describe how to perform ratiometric quantification of FRET efficiency on a pixel-by-pixel basis using Harmony® High Content Analysis Software.